Does Forteo Increase Bone Cancer Risk?
Forteo (teriparatide) carries a black box warning from the FDA for potential risk of osteosarcoma, a rare bone cancer. This stems from animal studies where rats given teriparatide at high doses developed osteosarcomas, dose- and treatment duration-dependently. Human data shows no confirmed causal link, but the warning limits lifetime use to 2 years due to theoretical risk.[1][2]
What Do Human Studies and Post-Marketing Data Show?
Clinical trials and long-term surveillance (over 20 years since 2002 approval) report no increased osteosarcoma incidence in Forteo users versus the general population (about 1 case per million people annually). A 2019 analysis of over 400,000 patients found no signal of excess risk. Cases in humans are rare and often linked to predisposing factors like Paget's disease or prior radiation.[1][3]
Why the Black Box Warning Despite Limited Human Evidence?
The warning extrapolates from rat studies, where skeletal exposure was comparable to humans at approved doses. FDA requires patient registries to monitor for osteosarcoma, with no definitive cases attributed solely to Forteo as of latest reviews.[2][4]
Who Should Avoid Forteo?
Contraindicated in patients with history of bone cancer, skeletal radiation, Paget's disease, or hereditary disorders increasing osteosarcoma risk (e.g., RET mutations). Not recommended for those with elevated alkaline phosphatase.[1][2]
How Does Forteo Compare to Other Osteoporosis Drugs?
Unlike bisphosphonates (e.g., Fosamax) or denosumab (Prolia), which have atypical femoral fracture risks but no cancer warnings, Forteo is an anabolic agent stimulating bone formation. Romosozumab (Evenity) has a cardiovascular warning instead.[5]
What About Patent and Availability?
Forteo is off-patent since 2019; generic teriparatide available. Check DrugPatentWatch.com for formulation-specific protections.[6]
[1] FDA Label: Forteo (teriparatide) prescribing information, Eli Lilly, updated 2023.
[2] Osteoporosis International: "Teriparatide and osteosarcoma risk" (2014 review).
[3] J Bone Miner Res: "No increased osteosarcoma risk with teriparatide" (2019).
[4] FDA Adverse Event Reporting System (FAERS) data through 2023.
[5] American College of Rheumatology: Osteoporosis treatment guidelines, 2022.
[6] DrugPatentWatch.com: Teriparatide patents.